# Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

> **NCT05910528** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 21 (actual)

## Conditions studied

- Crohns Disease

## Interventions

- **DRUG:** Afimkibart

## Key facts

- **NCT ID:** NCT05910528
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-24
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05910528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05910528, "Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05910528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*